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Electrocardiographic abnormalities and uremic cardiomyopa-
thy.
Background. Progressive renal disease is associated with
an increased risk of cardiovascular death, specifically sudden
death. We investigated the link between uremic cardiomyopa-
thy, QT interval and dispersal, and arrhythmias (by ambulatory
ECG monitoring) in patients at different stages of progressive
renal disease.
Methods. In a cross-sectional study we investigated 296 pa-
tients with nondiabetic renal disease (53 transplant recipients,
55 hemodialysis patients, and 188 throughout the range of
chronic renal failure). Patients underwent echocardiography,
ECG, and ambulatory blood pressure and ECG monitoring.
Results. Left ventricular mass was increased from the earliest
stages of renal disease (near-normal renal function), the pre-
dominant pattern being eccentric left ventricular hypertrophy
(LVH). There was a progressive increase in LVH with loss of
renal function, so that more than 80% of patients on renal re-
placement therapy have LVH, the dominant pattern being con-
centric LVH. The prevalence of diastolic dysfunction increased
in parallel with changes in left ventricular mass but systolic dys-
function and ventricular dilatation did not. Increased QT inter-
val and QT dispersal were associated with poor renal function
(maximal in dialysis patients), and were linked to LVH and
other echocardiographic abnormalities. Arrhythmias were un-
common on ambulatory recording but were more common with
poor renal function, in the presence of uremic cardiomyopathy,
and increased QT interval and dispersal.
Conclusion. LVH is present from the earliest stages of pro-
gressive renal disease. This, and other forms of uremic car-
diomyopathy, is linked to increased QT interval and dispersal,
and with minor rhythm abnormalities, providing a link with the
high risk of sudden death in this population.
The use of dialysis and transplantation has greatly im-
proved the outlook for patients with chronic renal failure.
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However, affected patients continue to die prematurely,
the leading cause of death being premature cardiovas-
cular disease (CVD) [1, 2]. Although patients with re-
nal disease have many conventional risk factors for CVD
(e.g., hypertension and hypercholesterolemia), these risk
factors may have less impact than in the general popu-
lation [2, 3, 4, 5]. The pattern of CVD, specifically, the
cause of death, also differs from the general population
with a disproportionate increase in the incidence of sud-
den death, rather than myocardial infarction. Echocar-
diographic studies have reported a high prevalence of
cardiac abnormalities in patients with end-stage renal
failure (ESRF), specifically, left ventricular hypertrophy
(LVH), systolic or diastolic dysfunction, and ventricular
dilatation (dilated cardiomyopathy) [6–11]. These are as-
sociated more strongly with an adverse prognosis than
conventional cardiovascular risk factors [8, 10], even
when adjusted for the presence of coronary artery disease
[7], and may provide an explanation for the high incidence
of sudden death in this population. Increased QT inter-
val and dispersal on an electrocardiogram (ECG) is asso-
ciated with LVH, the development of arrhythmias, and
sudden cardiac death in other patient groups. Recent
studies have suggested a similar relationship with out-
come in patients with ESRF [12]. We, and others, have
shown that QT dispersal is increased in patients with
ESRF (including transplant recipients) and may be as-
sociated with LVH [13–20]. This is consistent with the
hypothesis that LVH and related echocardiographic ab-
normalities are associated with increased QT dispersal
and, hence, the development of arrhythmias (which may
lead to sudden cardiac death) in patients with primary and
progressive renal diseases (PRD) [21]. Whether these ab-
normalities are limited to ESRF or develop earlier in the
natural history of PRD is unknown.
The aim of the present study was to investigate the
development of uremic cardiomyopathy; and the rela-
tionship between echocardiographic abnormalities, QT
parameters, and arrhythmias (detected by 24-hour am-
bulatory ECG recording) in a cross-sectional study of
patients at different stages of PRD.
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METHODS
Patients were recruited from the Renal Unit at the
Western Infirmary, Glasgow, Scotland in the calendar
years 1998 and 1999. This unit serves approximately 5000
patients, including 270 to 300 on regular dialysis and 700
to 800 renal transplant recipients. The study had a cross-
sectional design. It formed the baseline assessment of
the West of Scotland Kidney Disease Study into cardio-
vascular complications of renal disease; interval assess-
ment of the patients is ongoing. The target was to recruit
approximately 50 patients on hemodialysis, 50 patients
with a functioning renal allograft, and 200 patients with
proven renal disease not requiring renal replacement
therapy. This latter group was subdivided into quartiles
according to renal function of the participating patients
(based on serum creatinine <120, 120–200, 200–400, and
>400 lmol/L). Within these 6 groups, patients were con-
tacted randomly, using a published approach [22, 23] to
identify a representative, unbiased population of patients.
As a control group for the echocardiographic study, pa-
tients were matched for age and sex with normal subjects
from the same geographic area who were recruited in a
similar randomized manner, and in whom echocardiogra-
phy was performed (by the same echocardiographer; ER)
as part of the MONICA study [22, 23]. Patients with dia-
betes mellitus, overt heart failure, and/or coronary heart
disease (i.e., patients with angina, use of nitrates, or a
history of myocardial infarction) were excluded. Control
subjects were excluded if they had a history of hyperten-
sion, CVD, or renal disease. The protocol was approved
by the hospital Ethics Committee, and all patients gave
written informed consent.
Measurements
Each patient underwent the following investigations:
echocardiography, 24-hour ambulatory blood pressure,
and clinic blood pressure measurements as previously
described [24], weight and height, 12-lead ECG, and 24-
hour ambulatory ECG. Blood was taken after 30 minutes
rest for routine hematology and biochemistry, and plasma
samples stored for subsequent analyses. In addition, all
patients completed a questionnaire on demographic pa-
rameters, medical history, and current medication [23].
These investigations were performed on the same day;
the patient returned the following day for removal of the
ambulatory blood pressure and ECG monitors.
Echocardiography was performed by one experienced
cardiac technician (ER) as previously described [10,
24] using an Acuson 128 machine (Siemens Medical,
Bracknell, UK). The video images were analyzed by
one experienced observer, blinded to the identity of the
patients or controls and their clinical status (GS). Left
ventricular (LV) dimensions were determined from two-
dimensional guided M-mode images, using American
Society of Echocardiography leading edge recommen-
dations [10, 24, 25]. The mean of 3 measurements was
taken. Where appropriate, echocardiographic measure-
ments were performed on the morning after hemodialy-
sis, as recommended by Parfrey et al [26]. LV mass was
calculated by the method of Devereux and Reichek [27]:
LVmass = 1.04 × [(IVSTd + PWTd + LVIDd)3
−LVID3d
] − 13.6g
where IVSTd is interventricular septal thickness in di-
astole, PWTd is posterior wall thickness in diastole, and
LVIDd is left ventricular internal diameter in diastole.
LV mass index (LVMI) was calculated by dividing LV
mass by body surface area. LVH was defined as a LVMI
of more than 131 g/m2 in men, and more than 100 g/m2
in women [10, 27]. Further characterization of LVH into
concentric and eccentric hypertrophy was dependent on
measurements of relative wall thickness (RWT) accord-
ing to American Society of Echocardiography criteria:
(RWT = [(2 × PWTd)/LVIDd]
Concentric hypertrophy was present if the RWT was
greater than 0.45 in the presence of LVH. Eccentric hy-
pertrophy was present if the RWT was less than 0.45 in
the presence of LVH. Systolic function was assessed by
measuring LV ejection fraction (EF) from the mean of
3 measurements in different cardiac cycles using the bi-
plane disc summation method [22, 23], and by calculation
of fractional shortening (FS), from the reduction of LV
internal diameter during the cardiac cycle. Diastolic func-
tion was estimated by measuring the E:A ratio.
Clinic blood pressure measurements were made after
10 minutes of rest in a seated position using a standard
mercury sphygmomanometer according to the British
Hypertension Society guidelines, in both renal and con-
trol groups. The mean of 3 readings was recorded. Am-
bulatory blood pressure monitoring was performed using
a Spacelabs 90207 machine (Spacelabs, Dolby, Ltd.,
Stirling, UK), with a standard analysis package. The av-
erage daytime (07.00–23.00) and night time (23.00–07.00)
systolic and diastolic blood pressures were recorded, and
nocturnal dip calculated from the difference between
daytime and night time calculated mean arterial pres-
sure. A dip of more than 10 mm Hg was taken as nor-
mal. Ambulatory ECG monitoring was performed using
the Pathfinder analysis system (Reynolds Medical,
Hertford, UK) with semiautomated analysis. The number
of ectopics and the number of episodes of supraventric-
ular tachycardia (SVT) or ventricular tachycardia (VT),
defined as runs of 3 or more complexes (at more than
100 beats per minute), were recorded. Patients were ar-
bitrarily classified into those who had more (or less) than
6 ectopics per hour (in view of the very low number
of ectopics seen in most patients) and, separately, by
the presence—or absence—of short runs of SVT or VT.
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Table 1. Patient characteristics
Renal disease (quartiles of renal function)
1st 2nd 3rd 4th Hemodialysis Transplantation
Number 47 47 47 47 55 53
Sex M/F 29/18 27/20 19/28 16/31 33/22 31/22
Age years 40.7 ± 10.1 49.3 ± 12.3a 49.1 ± 13.0a 53.7 ± 13.9a 46.8 ± 14.1 42.1 ± 12.4
Height cm 171 ± 10 169 ± 10 164 ± 10a 166 ± 9 165 ± 11a 166 ± 10
Weight kg 81.6 ± 13.9 77.2 ± 15.5 71.2 ± 14.7a 67.6 ± 14.4a 66.6 ± 14.9a 70.1 ± 15.6a
Creat Cl mL/min 104.1 ± 22.6 56.5 ± 10.3a 31.3 ± 6.3a 14.1 ± 4.5a – 56.6 ± 21.5a
Renal diseases
PKD % 19 30 14 15 16 6
CPN % 15 11 15 23 16 25
IgA % 23 17 2 6 5 4
FGS % 0 4 2 6 7 8
Other % 36 30 38 40 44 55
Unknown % 6 9 26 9 11 4
Duration of renal disease years 5.7 (2.7–10.4) 7.6 (3.2–13.1) 5.0 (2.6–9.3) 4.8 (2.5–10.7) 7.5 (3.9–15.8) 17.5 (8.4–23.4)a
Duration after start RRT years 2.2 (0.8–5.1) 9.5 (4.9–16.8)
Duration after Tx years 6.1 (1.8–11.1)
aDBP mm Hg 81.3 ± 10.1 81.2 ± 8.5 80.1 ± 9.8 80.0 ± 9.5 82.8 ± 15.9 80.9 ± 8.0
aSBP mm Hg 130.9 ± 13.3 129.7 ± 11.9 128.5 ± 14.4 135.7 ± 16.0 135.8 ± 23.6 129.7 ± 11.3
Number of AHT 1.0 ± 1.1 1.2 ± 1.0 1.6 ± 1.3 2.1 ± 1.2a 0.6 ± 0.9 1.4 ± 1.0
Antihypertensive drugs (D/B/A) 3/9/17 5/14/14 11/22/19 18/22/15 6/9/2 10/29/10
Hb g/dL 13.8 ± 1.9 13.4 ± 1.7 11.8 ± 1.8a 10.7 ± 1.4a 11.2 ± 1.8a 12.2 ± 1.7a
CaPO4 2.24 ± 0.45 2.17 ± 0.41 2.66 ± 0.53 3.48 ± 0.68a 4.39 ± 1.22a 2.43 ± 0.85
PTH pmol/L 3.6 (2.9–5.5) 5.6 (3.8–8.3) 12.2 (6.6–22.8)a 33.0 (20.1–56.3)a 41.4 (20.0–69.5)a 8.1 (4.6–15.0)a
Abbreviations are: PKD, adult polycystic kidney disease; CPN, chronic pyelonephritis/reflux nephropathy; IgA, IgA nephropathy; FGS, focal glomerulosclerosis;
other, other proven diagnoses; AHT, antihypertensive drugs; RRT, renal replacement therapy; Tx, renal transplantation; aDBP, mean ambulatory diastolic blood
pressure; aSBP, mean ambulatory systolic blood pressure; AHT, antihypertensive agents; D/B/A, loop diuretic/beta blocker/ACE inhibitor, angiotensin receptor
antagonist (n); Hb, hemoglobin concentration; CaPO4, calcium phosphate product (mmol/L); PTH, parathyroid hormone. Data are shown as mean ± SD or median
(interquartile range). Variables as listed.
aP < 0.05 vs. patients with renal disease with near-normal renal function (1st quartile) (ANOVA).
Ambulatory ECG and blood pressure studies were not
available for the control subjects. A standard 12-lead
ECG was examined for LVH using Cornell criteria [19,
20]. QT interval (QTc) and QT dispersal (QTcd) were
measured manually, using a digitizing tablet on enlarged
tracings (as previously described [19]) and corrected for
heart rate using Bazett’s formula [19, 20].
Assessment of routine hematologic and biochemical
parameters was performed by autoanalyzer in the rou-
tine clinical laboratory. The calcium phosphate product
was calculated using serum calcium concentrations, cor-
rected for serum albumin concentration. Renal function
was estimated using the Cockroft-Gault formula.
Statistical methods
Data are expressed as mean (standard deviation) for
normally distributed variables or as median [interquar-
tile range] for non-normally distributed data. Compar-
isons between the patient groups and their age- and
sex-matched control groups were made by using Student
t test or Wilcoxon rank-sum tests for normally and non-
normally distributed data, respectively. Categorical vari-
ables were compared using the chi-square test. Data in
the various groups of patients with renal disease were
compared to data obtained in the group of patients with
chronic renal failure and near-normal renal function (i.e.,
first quartile of renal function) using a one-way analysis
of variance (ANOVA) with Tukey’s pairwise comparison
procedure to control for multiple testing. All tests were
two-tailed, with P < 0.05 taken to indicate statistical sig-
nificance.
The determinants of QTc, QTcd, and LVMI were an-
alyzed by linear regression analysis using a stepwise
method. All analyses were performed using SPSS V9.0
(SPSS, Inc., Chicago, IL, USA).
RESULTS
Echocardiography was performed in 308 patients. Af-
ter analysis of questionnaires and patient files, 12 patients
were excluded (9 had diabetic nephropathy, 1 had proven
coronary heart disease, and in 2 patients echocardiogra-
phy was performed immediately before dialysis). Demo-
graphic data on the remaining 296 patients are shown in
Table 1. Fifty-three patients with a renal allograft entered
the study, 55 patients on hemodialysis, and 188 patients
with proven primary renal disease not requiring renal re-
placement therapy. This latter group of patients was sub-
divided into quartiles (of 47 patients) according to their
calculated creatinine clearance: (1) 163 to 75 mL/min; (2)
74 to 44 mL/min; (3) 43 to 22 mL/min; (4) 21 to 4 mL/min.
The largest diagnostic group of patients had polycystic
kidney disease; the second most prevalent renal disease
was chronic pyelonephritis. The duration of renal disease
ranged from 0.3 to 38 years, and was longer, predictably,
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Table 2. Echocardiographic values for the study population and matched controls
Renal disease (quartiles of renal function)
1st 2nd 3rd 4th Hemodialysis Transplantation
Number 47 47 47 47 55 53
Sex M/F P 29/18 27/20 19/28 16/31 33/22 31/22
Age years P 40.7 ± 10.1 49.3 ± 12.3a 49.1 ± 13.0a 53.7 ± 13.9a 46.8 ± 14.1 42.1 ± 12.4
C 40.9 ± 9.7 49.5 ± 11.9b 49.2 ± 12.2b 53.8 ± 13.6b 47.0 ± 13.8 42.6 ± 12.2
IVSTd cm P 1.13 ± 0.50c 1.05 ± 0.28c 1.04 ± 0.27c 1.15 ± 0.37c 1.19 ± 0.39c 1.23 ± 0.37c
C 0.82 ± 0.21 0.88 ± 0.24 0.91 ± 0.27 0.89 ± 0.20 0.86 ± 0.23 0.84 ± 0.22
PWTd cm P 0.99 ± 0.19c 0.95 ± 0.26c 1.00 ± 0.14c 1.05 ± 0.26c 1.18 ± 0.28a,c 1.10 ± 0.24c
C 0.73 ± 0.18 0.72 ± 0.15 0.81 ± 0.20 0.81 ± 0.17 0.83 ± 0.18b 0.80 ± 0.15
LVIDd cm P 4.95 ± 0.49 4.95 ± 0.65 4.76 ± 0.55 4.86 ± 0.67 4.98 ± 0.75 4.89 ± 0.65
C 5.15 ± 0.57 5.17 ± 0.58 4.92 ± 0.65 4.87 ± 0.61 5.02 ± 0.57 4.87 ± 0.46
LVM g P 224 ± 71c 212 ± 71c 214 ± 67c 229 ± 92c 281 ± 125a,c 254 ± 88c
C 173 ± 62 176 ± 59 178 ± 70 163 ± 51 179 ± 53 166 ± 54
LVMI g/m2 P 116.5 ± 32.3c 112.5 ± 33.9c 119.1 ± 29.4c 129.7 ± 43.3c 161.8 ± 69.5a,c 145.5 ± 43.0a,c
C 92.9 ± 26.3 97.0 ± 28.1 98.7 ± 32.4 94.2 ± 25.4 98.7 ± 24.1 91.1 ± 24.9
FS% P 33.8 ± 7.4 33.8 ± 8.3 32.5 ± 6.7 35.2 ± 6.9 31.6 ± 8.0 33.8 ± 7.8
C 31.2 ± 6.6 31.6 ± 5.8 32.5 ± 6.9 32.5 ± 8.3 32.1 ± 5.1 33.3 ± 7.1
EF% P 50.8 ± 7.5 53.0 ± 8.5 53.8 ± 7.6 52.2 ± 7.1 51.1 ± 7.8 55.8 ± 7.2
C 46.0 ± 6.8 47.9 ± 8.0 48.1 ± 7.5 48.3 ± 7.1 47.0 ± 8.3 47.1 ± 8.2
E:A ratio P 1.33 ± 0.48 1.13 ± 0.46 1.13 ± 0.32 1.03 ± 0.32 0.92 ± 0.38 1.28 ± 0.49
C 1.37 ± 0.38 1.26 ± 0.57 1.22 ± 0.40 1.19 ± 0.45 1.27 ± 0.47 1.39 ± 0.52
Abbreviations are: IVSTd, interventricular septal thickness in diastole; PWTd, posterior wall thickness in diastole; LVIDd, left ventricular internal diameter in
diastole; LVM, left ventricular mass; LVMI, left ventricular mass index; EF, ejection fraction; FS, fractional shortening; E:A ratio, diastolic function.
aP < 0.05 vs. patients with renal disease with near-normal renal function (1st quartile) (ANOVA with Tukey’s correction).
bP < 0.05 vs. controls matched for patients with renal disease with near-normal renal function (1st quartile) (ANOVA with Tukey’s correction).
cP < 0.05 vs. corresponding age- and sex-matched control group (Student t test).
in the patients on hemodialysis and in the transplanted
patients. The limited demographic data on the control
population are as follows (mean ± SD): age 47.0 ± 10.4,
weight 71.0 ± 10.4 kg, SBP 126 ± 17 mm Hg, DBP 79 ±
9 mm Hg.
Echocardiographic abnormalities
LVMI was greater than the matched controls even
in the group of patients with near-normal renal func-
tion (Table 2, Fig. 1). Patients with poorer renal func-
tion tended to have higher LVMI. LVMI was highest in
patients receiving hemodialysis treatment; transplant re-
cipients had lower values than dialysis patients, although
LVMI was still elevated in this group. Differences in
LVMI between the various groups were due to differ-
ences in interventricular wall thickness and posterior wall
thickness (Table 2), and are thus likely to be genuine,
rather than an artifact of echocardiographic measure-
ments [24]. The observed differences in LVMI (in the
study groups) may be underestimated by variation in the
proportion of women in each group (Fig. 1, Table 1). How-
ever, the incidence of LVH (corrected for sex, Fig. 2)
ranged from 39% in the group of patients with near-
normal renal function (1st quartile) to 80% in the group
with a renal allograft, whereas in the various control
groups the incidence varied around 20% (Fig. 2). The
high prevalence of LVH in the groups with poorer re-
nal function is due to increased prevalence of concen-
tric hypertrophy with declining renal function, and to a
high overall prevalence of eccentric hypertrophy (Fig. 2).
Virtually none of the controls showed concentric LVH,
although 17% fulfilled the criteria for eccentric LVH.
We observed no differences between the patient groups
and their matched controls in left ventricular internal di-
ameter, or in the number of patients who fulfilled the
criteria for dilated uremic cardiomyopathy (end diastolic
volume >90 mL; Fig. 2) [10]. LV systolic function was
determined by measurement of ejection fraction. There
was no trend toward reduction in ejection fraction in the
presence of reduced renal function (Fig. 1), and ejection
fraction was significantly higher in all groups of patients
with renal disease when compared with controls. The pro-
portion of patients who fulfilled the criteria for a diagno-
sis of systolic dysfunction (ejection fraction <50%) [10]
shows a similar pattern, with fewer patients in the CRF
groups having this abnormality compared with controls
(Fig. 2).
Left ventricular diastolic function was assessed by mea-
surement of the E:A ratio (Fig. 1). Within the limita-
tions of this parameter, the ratio was lower in the groups
with poorer renal function compared to those with near-
normal function. However, a similar pattern was evident
in the matched control groups, and reflects the older age
of patients with more advanced renal disease. Only in the
patients on hemodialysis was a statistically significant dif-
ference present, patients having a lower E:A ratio. How-
ever, when diastolic dysfunction is defined as an E:A ratio
of less than 1, the incidence in the 6 groups of patients
with renal disease was 23, 36, 43, 55, 40, and 26%, whereas
in the sex- and age-matched control groups the incidence
was lower at 11, 15, 23, 28, 24, and 9%, respectively.
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Fig. 1. Main echocardiographic findings (mean and standard devia-
tions) for the study population (squares) and controls (circles). Abbre-
viations are: LVMI, left ventricular mass index; EF, ejection fraction; FS,
fractional shortening; E:A ratio (diastolic function). ∗P < 0.05 vs. pa-
tients with renal disease with near-normal renal function (1st quartile).
#P < 0.05 vs. corresponding age- and sex-matched control group.
Electrocardiographic abnormalities
The ECG data are shown in Figure 3. QTc and QTcd
were 418.0 ± 24.7 and 49.8 ± 17.8 milliseconds (mean ±
SD), respectively, in patients with near-normal renal func-
tion (quartile 1). There was little difference in either QTc
or QTcd between the patients with more advanced renal
failure and normal renal function. However, the values
were significantly higher in dialysis patients (474.1 ± 34.3;
61.7 ± 24.9 ms) and, to a lesser extent, in transplant re-
cipients (431.3 ± 23.3; 51.6 ± 20.6 ms), respectively.
Ambulatory ECG recordings were successful in 240
patients. We did not expect a high prevalence of serious
abnormalities in these asymptomatic patients, and it is
necessary to look for relatively subtle changes. The me-
dian number of ventricular ectopics per hour was 0.33
(renal function—quartile 1), 0.59 (Q2), 0.35 (Q3), 1.12
(Q4), 1.08 (hemodialysis), 0.62 (transplant). In a previ-
ous study from our group [28], a threshold of 30 ventric-
ular ectopics per hour was used to identify patients with
a “significant” potential for arrhythmias. However, this
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Fig. 2. Left ventricular abnormalities in patients with renal disease.
CRF 1–4 are the four groups with primary and progressive renal disease;
HD and Tx are the hemodialysis and transplant groups. The upper panel
shows the proportion of patients (%) with ECG evidence of LVH. The
second panel shows the proportion with echocardiographic evidence of
LVH- the hatched bar is eccentric LVH, the open bar concentric LVH.
The third panel shows the proportion (%) with dilated cardiomyopa-
thy (DCM), and the bottom panel the proportion (%) with systolic
dysfunction (LVSD).
excluded all but 22 of the patients in the current study.
Previous reports in dialysis patients observed more ec-
topics but included the peridialytic period [21, 29, 30,
31]. We therefore, arbitrarily, used a reduced threshold
of 6 ectopics per hour (150 per day) corresponding to the
average ectopic rate reported in the interdialytic period
by Kayatas et al [30]. There was no increase in the pro-
portion of patients with this finding at any stage of pro-
gressive renal disease, but an increase (of around 50%)
in the patients on hemodialysis and transplant recipi-
ents. A further classification was based on the patients
who had short runs (more than 3 complexes at a rate of
>120/min) of ventricular or supraventricular complexes.
Once more, there was no trend in the PRD groups but a
higher prevalence—significant in the transplant group—
in patients with ESRF (Fig. 3).
To investigate a link between echocardiographic abnor-
malities and electrocardiographic indices, we compared
QT parameters and the prevalence of abnormalities
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Table 3. Electrocardiographic abnormalities in uremic cardiomyopathy
Group QTc QTcd >6 VE/hr SVT/VT
LVH (ECG) + 444.7 ± 44.2a 55.3 ± 17.9 22/56 (39.3%) 12/56 (21.4%)
LVH (ECG) − 431.6 ± 33.9 50.5 ± 20.3 76/184 (41.3%) 24/184 (13.0%)
LVH (Echo) + 441.0 ± 35.1c 54.2 ± 19.9a 54/137 (39.4%) 19/137 (13.9%)
Conc LVH 434.9 ± 36.2a 52.4 ± 19.4 25/78 (32.1%) 13/78 (16.7%)
Ecc LVH 450.0 ± 33.8c 55.6 ± 20.6a 26/54 (48.1%) 6/54 (11.1%)
LVH (Echo) − 423.4 ± 31.8 48.8 ± 17.9 44/99 (44.4%) 15/99 (15.2%)
LVSD (FS) + 453.3 ± 49.6c 58.4 ± 24.5a 20/31 (64.6%)b 10/31 (32.3%)b
LVSD (FS) − 431.3 ± 31.8 51.2 ± 18.6 78/205 (38.0%) 24/205 (11.7%)
LVSD (EF) + 444.7 ± 50.8a 55.3 ± 20.6 33/74 (44.6%) 10/74 (13.5%)
LVSD (EF) − 430.6 ± 33.4 50.7 ± 28.3 65/165 (39.4%) 23/165 (13.9%)
DCM + 444.7 ± 44.2a 55.3 ± 18.0 28/56 (50.0%) 11/56 (19.6%)
DCM − 431.1 ± 26.1 50.5 ± 25.1 66/109 (37.7%) 21/175 (12.0%)
Data on corrected QT interval (QTc; ms ± SD), corrected QT dispersal (QTcd; ms ± SD), the proportion of patients with more than 6 ventricular ectopics per hour
(>6 VE/hr), and the proportion of patients with runs of supraventricular or ventricular tachycardia (SVT/VT, see text for definition).
+/− Represents the presence (+) or absence (−) of left ventricular hypertrophy by ECG [LVH (ECG)], LVH by echocardiography [LVH (echo)], and subgroups of
concentric (concLVH) or eccentric (eccLVH) hypertrophy, systolic dysfunction by fractional shortening [LVSD (FS)] and ejection fraction [LVSD (EF)], and dilated
cardiomyopathy (DCM).
aP < 0.05, bP < 0.01, cP < 0.001 by ANOVA for continuous data, chi-square for categorical data vs. negative group.
on ambulatory ECG recording in patients, subgrouped
by the presence of echocardiographic abnormalities
(Table 3). QT interval was higher (by approximately 5%)
in patients with each form of uremic cardiomyopathy
when compared to those without echocardiographic ab-
normalities. QT dispersal showed a similar but mostly
nonsignificant trend. Ambulatory ECG recording also re-
vealed trend toward a higher prevalence of ECG abnor-
malities (ectopics, runs of SVT and VT) in the presence
of uremic cardiomyopathy compared to those without
echocardiographic abnormalities. However, this achieves
statistical significance only in those patients with systolic
dysfunction, measured by fractional shortening (Table 3).
We performed a multivariate linear regression analysis
to investigate the relationships between QT parameters,
and cardiac structure and function. These data, and the
factors with significance in one or more models are re-
ported in Table 4. In the multivariate model (R2, 0.467),
QT interval was uniquely related to LVMI, ejection frac-
tion, E:A ratio, and end diastolic volume. Thus, ventric-
ular mass, dilatation, systolic and diastolic function, all
show an appropriate relationship with QT interval. The
other major determinants of increased QT interval in
this analysis were low creatinine clearance, low serum
potassium concentration, low body mass index, and fe-
male sex. The same analysis identified fewer significant
parameters related to QTcd in the multivariate linear re-
gression model, with a low R2 value (0.228), which limits
the significance of the findings. However, higher LVMI
and lower ejection fraction values had the strongest spe-
cific relationship with increased QT dispersal. Low BMI
and high hemoglobin values were also related to QT dis-
persal, albeit with lesser statistical significance. A similar
analysis of the determinants of LVMI was performed. The
best model (R2, 0.61) identified 9 parameters specifically
related to LV mass. These include established determi-
nants of LV mass in other populations—age, sex, BMI,
and blood pressure. Low ejection fraction and ventricu-
lar dilatation were also related to LVMI, consistent with
clustering of different forms of uremic cardiomyopathy
and the dependence of the Devereux and Reichek equa-
tion on ventricular dimensions [24]. Low hemoglobin was
also related to LVMI, as were calcium-phosphate product
and the status of the patient (CRF vs., HD vs., transplant).
These findings are consistent with the findings of previous
studies on the determinants of LV mass (e.g., [32]).
DISCUSSION
The aim of this study was to examine the develop-
ment of echocardiographic and electrocardiographic ab-
normalities in patients with CRF, in a relatively large
cross-sectional study [11, 33]. Cardiovascular mortality
is greatly increased in patients on dialysis therapy and, to
a lesser extent, in patients with functioning transplants.
However, when CV risk (and the associated risk factors)
begins to increase during progressive renal impairment
is incompletely understood, although recent studies sug-
gest that even in the earliest stages of renal failure (when
serum creatinine is less than twice normal) CV risk is
increased [34, 35].
This cross-sectional study provides an approach to
the evolution of these abnormalities with progressive
renal disease, and a means of studying the potential
link between structural cardiac abnormalities and sud-
den cardiac death. Although a longitudinal study would
be preferable, progression of renal disease is too slow to
permit this approach in a single center. It should be recog-
nized that not all patients with good function (e.g., group
CRF1) will necessarily progress, and some patients in this
group have exceptionally good function. The study links
several aspects (ambulatory ECG, ABPM, and echocar-
diography) that have not previously been studied to-
gether. We found that echocardiographic abnormalities
develop early in the natural history of renal disease, and
Stewart et al: Arrhythmias and cardiomyopathy in uremia 223
Table 4. Multivariate regression analyses of QTc, QTcd, and LVMI
QTc QTcd LVMI
Parameter Beta (SD) P value Beta (SD) P value Beta (SD) P value
F 28.397 (P < 0.0001) 19.365 (P < 0.0001) 44.775 (P < 0.0001)
R2 0.467 0.228 0.610
Constant 553.766 (24.383) 50.302 (11.601) −34.0 (27.1)
LVMI 0.474 (0.049) <0.001 0.253 (0.030) <0.001 0.464 (0.217) 0.033
EF −1.101 (0.233) <0.001 −0.504 (0.141) <0.001 – –
Ct. Cl. −1.185 (0.062) 0.003 – – – –
K −16.503 (3.370) <0.001 – – – –
Sex 19.681 (4.191) <0.001 – – −36.569 (3.811) <0.001
BMI −2.222 (0.449) <0.001 −0.887 (0.260) 0.001 3.325 (0.386) <0.001
E:A −16.515 (4.255) <0.001 – – – –
EDV 0.150 (0.066) 0.024 – – −0.332 (0.063) <0.001
Hb – – 1.794 (0.612) 0.020 −6.186 (0.929) <0.001
aSBP – – – – 1.067 (0.107) <0.001
Status – – – – 14.671 (2.185) <0.001
Ca×P04 – – – – 6.265 (1.593) <0.001
Age – – – – 0.318 (0.129) 0.015
Diabetes – – – – – –
Abbreviations are: QTc, corrected QT interval; QTcd, corrected QT dispersal; LVMI, left ventricular mass index (g/m2); EF, echocardiographic ejection fraction
(%); Ct. Cl., Cockroft-Gault estimated creatinine clearance (mL/min); sex, male = 1, female = 2; BMI, body mass index (kg/m2); E:A, diastolic function (E:A ratio);
EDV, end diastolic volume (mL); Hb, hemoglobin (g/dL); aSBP, ambulatory SBP (mm Hg); Status, CRF-1, HD-2, Tx-3; Age (years); K, serum potassium (mmol/L);
Ca×PO4, serum calcium phosphate product (mmol/L); diabetes, diabetes = 1, no diabetes = 0. Multivariate linear regression analysis for QTc, QTcd, and LVMI. F
value (P value), R2, and constant for best-fit model. Beta (SD) are shown for significant variables. The variables in the parameter column were included in the analyses;
those without values were excluded in the step-wise analysis.
that LVH is the most prevalent and potentially reversible
anomaly. ECG abnormalities (prolonged QT interval,
increased QT dispersal, frequency of ectopics and
tachyarrhythmias) are more common in patients with
advanced renal disease, including transplant recipients,
and in patients with uremic cardiomyopathy. Thus, the
findings are consistent with a possible link between ure-
mic cardiomyopathy and the risk of sudden (presumed
arrhythmic) death in patients with primary and progres-
sive renal disease.
To limit the effect of selection bias in this study, patients
were selected at random from a list of all eligible patients,
using a strategy that we have previously employed [22,
23]. This allowed comparison with a similarly selected
age- and sex-matched normal control group, lacking in
most of the previous studies. The average age was higher
in the groups with advanced renal impairment, reflect-
ing the natural history of PRD, but because age is the
major determinant of survival in patients on RRT, the
average age of patients in the hemodialysis and transplan-
tation groups was lower than those with advanced CRF.
A second observation was that body weight was lower in
patients with advanced CRF, presumably a reflection of
relative undernutrition in an aging group of patients with
more advanced renal failure. While not unexpected, this
may also impact on measurements of LV mass. Therefore,
the control group was matched for age, sex, and height,
and a separate analysis was performed where LV mass
was corrected for height rather than BMI. However, this
did not alter the findings, and the results reported were
corrected for BMI. There were other predictable trends
in the population demographics. For example, poorer re-
nal function was accompanied by a reduced proportion
of women, an increase in the number of antihyperten-
sive agents, increased Ca × PO4 product and parathyroid
hormone (PTH) concentration, and reduced hemoglobin
concentration. However, the treated blood pressure lev-
els were similar across the groups. These data are shown
in Table 1.
Echocardiographic abnormalities
Several echocardiographic abnormalities have been
identified in patients with ESRF and are associated with
an adverse outcome. These have been characterized by
Parfrey et al [8] and include LVH, dilated cardiomy-
opathy, and systolic dysfunction. The natural history of
these abnormalities, with the exception of LVH [9, 11,
33], is not well known and was one aim of our study.
Previous studies have shown evidence of LVH in pa-
tients with IgA nephropathy and adult polycystic kidney
disease with near-normal renal function [36, 37, 38], al-
though this has not been an invariable finding [39]. We
confirm, in a larger population of patients with diverse
renal disease, that LVH, like hypertension, is likely to de-
velop in the earliest phases of all forms of renal disease.
There was a trend toward higher LVMI in the groups with
poorer renal function (Fig. 1), and a sequential increase
in the proportion of patients fulfilling the diagnostic cri-
teria for LVH supports this notion (see below; Fig. 2). LV
mass was significantly greater, and LVH was present in
the vast majority of patients on hemodialysis and follow-
ing transplantation (Fig. 1), albeit with the caveat that
echocardiography overestimates LV mass in hemodialy-
sis patients [24], and survival bias may be partly responsi-
ble for the lower LV mass in transplant recipients (Fig. 1).
Both the interventricular septal measurements and those
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Fig. 3. Electrocardiographic findings. QTc is the QT interval in mil-
liseconds, corrected for heart rate [19, 20], QTcd is corrected QT disper-
sal, and the lower two panels show the proportion of patients with more
than 6 ectopics (VE) per hour on Holter monitoring or the presence
of tachyarrhythmias (SVT/VT). The median number of VEs per hour
is as follows: CRF1-0.33, CRF2-0.59, CRF3-0.35, CRF4-1.12, HD-1.08,
Tx-0.62. Asterisks represent statistical significance: ∗P < 0.05, ∗∗P <
0.01, ∗∗∗P < 0.001 with respect to CRF group 1.
of posterior ventricular wall were significantly higher in
the hemodialysis group (Table 2), whereas there was no
difference in the left ventricular end diastolic diameter.
These observations suggest that there is a true increase
in LV mass in patients on hemodialysis compared with
predialysis patients. In the multivariate linear regression
analysis (Table 4), LVMI was predictably determined by
sex, BMI, age, blood pressure, and status (CRF vs., HD
vs., transplantation). There was an inverse relationship
between hemoglobin and LVMI as previously reported
[32], and Ca×PO4 product, that is likely to be due to asso-
ciated increase in vascular stiffness and hypertension [2].
There were also significant relationships between LVMI
and ejection fraction, E:A ratio, and an inverse relation-
ship with end diastolic volume, although it is difficult to
clarify causal relationships between these functionally re-
lated variables.
The pattern of changes in LVH is shown in Figure 2. Ec-
centric ventricular hypertrophy was approximately twice
as common in the patients with PRD, and there was about
a 10-fold increase in concentric LV hypertrophy com-
pared with the control group. Both increased progres-
sively with deteriorating function and were present in
30% to 40% of patients with advanced CRF or receiving
RRT. Thus, the majority of patients with advanced renal
failure have some form of LVH.
The development of systolic dysfunction, diastolic dys-
function, and “dilated cardiomyopathy” is less clear than
it is for LVH (Fig. 1). The full data are shown in Table 2.
There was neither a trend nor an absolute difference
between controls and patients in the measurement of
diastolic chamber diameter, nor was there a significant
pattern in the proportion of patients fulfilling the criteria
for a diagnosis of “dilated cardiomyopathy.” Systolic dys-
function, determined either by calculated ejection frac-
tion or fractional shortening (e.g., [10]), has also been
associated with adverse outcome in patients with ESRF.
Again, unexpectedly there was no change in ejection frac-
tion with deteriorating function, nor was there an increase
in the proportion of patients fulfilling the criteria for a di-
agnosis of systolic dysfunction. In fact, fewer patients with
CRF fulfilled the criteria for systolic dysfunction or di-
lated cardiomyopathy than controls, and only those in the
HD or transplant groups had a comparable prevalence.
The final parameter that we examined was the E:A ratio,
as a marker of diastolic dysfunction, albeit an imperfect
one. Although there was a progressive reduction in this
parameter with deteriorating renal function in keeping
with the observed increase in LVH, and the association
between LVH and diastolic dysfunction, these findings
were much less impressive when viewed with the data
from age- and sex-matched controls. A decrease in E:A
ratio with age is likely to explain the fall in this parameter
across the control groups and in the patients with PRD.
Electrocardiographic abnormalities
ECG evidence of LVH was common, and was approxi-
mately twice as common in patients with ESRF as in those
with CRF (Fig. 2). We have previously reported a high
prevalence of ECG-LVH in dialysis patients [19, 40] that
is associated with increased QT interval and dispersal [19,
20]. A similar pattern was seen in long-term transplant
survivors [20], in which increased QT dispersal was di-
rectly related to LV mass. In patients on hemodialysis, sys-
tolic dysfunction is associated with an increased incidence
of arrhythmias on Holter monitoring [41, 42], as is LVH
[43]. However, less is known about the association with
other patterns of uremic cardiomyopathy, or in asymp-
tomatic patients with renal disease. Moreover, little is
known about the evolution of QT abnormalities and ar-
rhythmias with progression of renal disease. We therefore
examined the development of QT abnormalities in our
study (Fig. 3). QT interval was increased in patients with
advanced and end-stage renal failure; QTcd shows a simi-
lar but less marked pattern. In the multivariate regression
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analysis (Table 4), QTc was dependent on LVMI, ejection
fraction, E:A ratio, and end-diastolic volume. These data
confirm the findings of more limited, small-scale studies
(e.g., [42]). Thus, mass, systolic and diastolic function, and
ventricular dilatation (the various patterns of uremic car-
diomyopathy [6, 8]) are associated with QT duration. The
analysis of QTcd showed a more limited dependence on
echocardiographic parameters—LVMI and ejection frac-
tion. When the patients were subgrouped according to
the presence or absence of echocardiographic abnormal-
ities (Table 3) there were significantly higher values of
QT interval and dispersal in the patients with each of the
echocardiographic patterns of uremic cardiomyopathy;
QTcd showed a similar, more limited, relationship. Linear
regression analysis identified significant, albeit modest re-
lationships between LVMI, EF, and QTcd consistent with
the relationship seen in Table 3 and for QTc (Table 4).
In addition, the multivariate analyses identified signifi-
cant relationships between QT interval and male sex, and
inverse relationships with serum potassium, renal func-
tion (Ct.Cl.), and body mass index. QTcd was dependent
on hemoglobin concentration and inversely on BMI. The
relationship with BMI is likely to reflect the changes in
body mass that accompany progression of renal disease
(Table 1). The inverse relationship between serum potas-
sium identifies one, possibly remediable, determinant
of QT duration. The positive relationship between
hemoglobin requires further investigation, although it
may provide an explanation for the “u”-shaped relation-
ship between hemoglobin levels and outcome in dialysis
patients [2].
The Holter ECG recordings show only minor abnor-
malities. Some previous studies in hemodialysis patients
have identified a high prevalence of ventricular dysrhyth-
mias, often complex rhythms likely to be associated with
a poor prognosis. However, these studies concentrated
on arrhythmias during and immediately after dialysis at a
time when there are major changes in serum electrolytes
and QT interval and dispersal [19, 30, 31, 44, 45]. The
prevalence of arrhythmias was much lower in the present
study, a reflection of the asymptomatic population, where
patients with diabetes and symptomatic ischemic heart
disease were specifically excluded, and where dialysis pa-
tients were studied on the postdialysis day. The analysis
therefore involves relatively minor abnormalities (fre-
quency of ventricular ectopics and short runs of SVT or
VT) that are not, by themselves, likely to be responsi-
ble for a major cardiac event. There is a trend for these
findings to be more common in patients with echocar-
diographic abnormalities and higher QTc or QTcd. The
opposite is also true. When the patients are divided into
those who have short runs of SVT or VT, the correspond-
ing values of QTC and QTcd are higher than those pa-
tients who do not have these ECG abnormalities. These
data therefore lend support to recent (largely small scale)
studies that have linked QTc and QTcd to various pat-
terns of uremic cardiomyopathy [21, 42, 43]. Both QTc
and QTcd are linked to adverse cardiac outcomes [21],
and a retrospective study suggests that this is likely to
be true in dialysis patients [12]. Recent studies have sug-
gested that the subdivision of patients into those with ec-
centric and concentric LVH may be of importance. In our
population, QTc was higher in patients with eccentric hy-
pertrophy when compared with concentric hypertrophy;
QTcd showed a similar trend but there was no significant
difference in the findings from 24-hour ECG recording.
The only group that had a significantly increased preva-
lence of arrhythmias was the group with systolic dysfunc-
tion (Table 3).
CONCLUSION
Although this study is cross-sectional in design, it is the
only study to target asymptomatic patients with varying
degrees of progressive renal impairment, with a matched
control group and concomitant ambulatory ECG record-
ing. We expected that there would be a progressive
increase in echocardiographic abnormalities from near-
normal levels in early PRD. Instead, we observed that
LVH was present in patients with proven primary renal
disease and normal or “near-normal” renal function, and
showed a trend toward increasing prevalence with dete-
riorating renal function. The pattern of LVH was unex-
pected, with eccentric hypertrophy being more common
in patients with good renal function and concentric LVH
increasing in prevalence as renal function deteriorates.
Despite the prognostic importance of systolic and dias-
tolic dysfunction, and “dilated” uremic cardiomyopathy
in patients with advanced CRF [8–11], we found much less
evidence of changes in these parameters with progres-
sion of renal disease, although diastolic function tended
to be worse and systolic function better than age- and
sex-matched controls at all stages of PRD.
QT parameters were increased in patients with ad-
vanced CRF and ESRF, and were associated with abnor-
malities (albeit minor) on ambulatory ECG recording,
including more frequent ventricular ectopics and short
bursts of tachycardia. As in other populations, QT dis-
persal is most closely associated with LV mass, but we
found a relationship with other patterns of uremic car-
diomyopathy and with arrhythmias. Although these data
are inconclusive, they do provide support for a link be-
tween uremic cardiomyopathy and sudden cardiac death
in this population. Moreover, they provide support for
the notion that prevention, or regression, of uremic car-
diomyopathy is likely to be at least as important as, for
example, statin therapy in the prevention of cardiovascu-
lar disease in patients with PRD.
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